In the bad old days of cancer treatment, it was the nasty side effects of chemotherapy that often ended up limiting treatment – and while checkpoint inhibitors have raised the bar in terms of efficacy and safety, they can have dangerous and unpleasant off-target consequences, too. Finding ways to focus the immune system on cancer and limiting any off-target effects will not only make checkpoint inhibitor therapy more tolerable but could also improve survival rates – and Sweden’s Ilya Pharma AB aims to do this with a novel approach combining synthetic biology with cell therapy.

Altesa Biosciences Inc. CEO Brett Giroir called the firm’s scientific co-founders George Painter and Dennis Liotta “the most important developers of drugs against viruses on the planet, and probably in history.” Giroir’s remarks came as the College Park, Ga.-based firm launched to develop and commercialize new antiviral drugs against common respiratory bugs such rhinovirus and parainfluenza, as well as vector-borne threats such as Dengue fever, yellow fever, Zika and Powassan.

Xanadu Bio, a Yale University spinout developing an intranasal SARS-CoV-2 mRNA vaccine booster, has secured an exclusive license from the school for a polymeric nanoparticle delivery platform to support the project. The delivery tech could potentially have future applications for influenza, respiratory syncytial virus and even cystic fibrosis.

The Royal Academy of Engineering in the U.K. has revealed a new batch of 70 entrepreneurs, including some developers of med-tech solutions, for its Leaders in Innovation Fellowships Global (LIF Global) program. This comes just two months after the LIF Advance edition of the initiative, which had 15 chosen. The selected entrepreneurs will receive equity-free support over the next six months from the training and mentorship program.

“The premise of our whole company is that we target molecular machines, but we don’t target the engine,” Adrian Schomburg told BioWorld. Instead, “we interfere with the throttle and other highly specific controls of these machines.” “We,” in this case, is Eisbach Bio GmbH, a German startup that is developing anticancer programs aimed at exploiting synthetic lethality by targeting helicases. Founded in 2019, the company has three programs, a recently announced collaboration with MD Anderson Cancer Center in oncology, and another program in COVID-19.

University of Edinburgh spinoff Biocaptiva Ltd. is taking its cell free DNA (cfDNA) capture device to clinical trials in 2022 following promising preclinical results. The company’s platform technology is designed to increase the quantity of cfDNA available for liquid biopsy testing. Current liquid biopsy practices obtain cfDNA via a venous blood draw but the concentration of tumor-derived ctDNA can be too low for comprehensive testing. Biocaptiva’ device emerged from research at the University of Edinburgh investigating liquid biopsy technologies.

Investors have backed a new precision medicine company targeting clonal hematopoiesis with $40 million. Tensixteen Bio Inc. is on a mission to understand how somatic mutations influence age-related diseases, including cancer. The San Francisco-based startup will use the funds to develop a genomics and clinical platform that can identify patients at high risk of developing disease.

PERTH, Australia – After raising AU$7.5 million (US$5.4 million) in a private placement, biopharma company Servatus Ltd. is advancing its microbial biotherapeutics clinical programs targeting serious autoimmune conditions. The Coolum, Queensland-based private company is focused on identifying and developing live microbial biotherapeutics and engineered proteins to treat chronic and autoimmune diseases, as well as non-antibiotic treatments for bacterial infections.

PERTH, Australia – After raising AU$7.5 million (US$5.4 million) in a private placement, biopharma company Servatus Ltd. is advancing its microbial biotherapeutics clinical programs targeting serious autoimmune conditions. The Coolum, Queensland-based private company is focused on identifying and developing live microbial biotherapeutics and engineered proteins to treat chronic and autoimmune diseases, as well as non-antibiotic treatments for bacterial infections.

Following Philip Morris International Inc.’s controversial takeover of respiratory drug firm Vectura plc, British American Tobacco plc (BAT) is also making inroads into medical research with U.K.-based Kbio Holdings Ltd., a biotech focused on plant-based medicine.